Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Rating of “Moderate Buy” by Brokerages

Tenax Therapeutics, Inc. (NASDAQ:TENX) has been given a consensus recommendation of “Moderate Buy” by the nine analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $14.00.

Several equities research analysts have recently commented on the company. Wall Street Zen downgraded Tenax Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday. Piper Sandler upped their price objective on shares of Tenax Therapeutics from $20.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, June 12th. Chardan Capital lowered Tenax Therapeutics from a “buy” rating to a “neutral” rating and set a $5.00 target price on the stock. in a research note on Tuesday, August 11th. Weiss Ratings cut shares of Tenax Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 11th. Finally, Roth Capital set a $5.00 price objective on shares of Tenax Therapeutics in a report on Monday, August 10th.

Tenax Therapeutics Stock Performance

Shares of NASDAQ TENX opened at $1.80 on Monday. The company has a fifty day moving average price of $12.85 and a 200 day moving average price of $13.01. The firm has a market cap of $67.36 million, a PE ratio of -1.22 and a beta of 0.93. Tenax Therapeutics has a 1-year low of $1.31 and a 1-year high of $19.40.

Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings results on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.03. Equities research analysts forecast that Tenax Therapeutics will post -1.41 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new stake in shares of Tenax Therapeutics in the 3rd quarter valued at $92,000. Letko Brosseau & Associates Inc. bought a new stake in shares of Tenax Therapeutics during the 4th quarter valued at approximately $130,000. Corient Private Wealth LLC bought a new stake in shares of Tenax Therapeutics during the fourth quarter worth $151,000. Quadrature Capital Ltd acquired a new position in Tenax Therapeutics in the 4th quarter worth about $252,000. Finally, Goldman Sachs Group Inc. acquired a new position in Tenax Therapeutics in the 4th quarter worth about $273,000. 1.67% of the stock is currently owned by institutional investors and hedge funds.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.